Chugai Pharmaceutical Co., Ltd. (4519.T) JPX
7,420.00
-198(-2.60%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
7,420.00
-198(-2.60%)
Currency In JPY
Address
Nihonbashi Mitsui Tower
Tokyo, 103-8324
Japan
Phone
81 3 3281 6611
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
5026
First IPO Date
January 04, 2000
| Name | Title | Pay | Year Born |
| Osamu Okuda | President, Chief Executive Officer & Chairman | 282M | 1963 |
| Nobuya Ishii | Head of Science & Technology Intelligence Dept. | 0 | N/A |
| Junichi Takano | Head of Marketing & Sales Division | 0 | N/A |
| Kosuke Iijima | Head of PHC Solution Department | 0 | N/A |
| Shinya Takuma | VP & Head of Manufacturing Technology Division | 0 | N/A |
| Toshiya Sasai | Executive of Investor Relations Group & Corporation Communications Department | 0 | N/A |
| Kaori Ouchi | Executive Vice President | 0 | N/A |
| Tomoyuki Igawa | Vice President & Head of Research Division | 0 | N/A |
| Shinji Hidaka | Executive Vice President | 0 | N/A |
| Tetsuya Yamaguchi | Executive Vice President | 0 | N/A |
| Iwaaki Taniguchi | Senior Executive Officer, CFO, Head of Finance & Director | 0 | 1966 |
| Yoshiyuki Yano | Executive Vice President | 0 | N/A |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.